The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the works performed neuroimaging new post, TAVR defects were observed in two-thirds of patients and this increases the risk of post clinical stroke.&nbsp; There is a missing data in the literature of<a href="https://solaci.org/en/2015/06/24/clean-tavi-transcatheter-aortic-valve-replacement-with-cerebral-protection/" title="Read more" >...</a>

Direct Flow Medical prosthesis is a nonmetallic, repositionable, recaptured valve (even after posts dilate), that does not require a pacemakers use during both implantation and post-dilatation.&nbsp; The aim of this study was to evaluate new valve results to one year in patients with symptomatic severe aortic stenosis with 19 and 26 mm ring, EuroScore of<a href="https://solaci.org/en/2015/06/24/discover-trial-results-at-one-year-of-the-new-nonmetallic-percutaneous-aortic-valve/" title="Read more" >...</a>

Aortic regurgitation after valve implantation has been shown to be a long -term mortality predictor. The aim of this study was to test the new Direct Flow Medical system, which is more flexible prosthesis with a lower profile that could result in minor aortic regurgitation and less need for post expansion. This multicenter study included<a href="https://solaci.org/en/2015/06/24/salus-new-percutaneous-valve-with-promising-results-regarding-aortic-regurgitation-post-implant/" title="Read more" >...</a>

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve Core with conventional surgery in patients at high surgical risk. Patients with a valve area &lt; 0.8 cm2 , valvular index &le; 0.5 cm2 , a mean gradient of &nbsp;&gt; 40 mmHg or peak speeds above 4m /s<a href="https://solaci.org/en/2015/06/24/corevalve-superior-to-surgical-aortic-valve-replacement-in-high-risk-patients/" title="Read more" >...</a>

So far, there had been no published randomized studies comparing balloon-expandable Edwards&rsquo;s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in<a href="https://solaci.org/en/2015/06/24/choice-trial-same-mortality-less-aortic-regurgitation-and-need-for-a-second-prosthetic-for-edwards-sapien-xt-valve-versus-medtronic-corevalve/" title="Read more" >...</a>

Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant in 2011 were included. As recommended in the European Cardiovascular Guidelines, this national registry suggests that percutaneous implant represents the dominant treatment of this disease, especially in high-risk patients. In high-risk<a href="https://solaci.org/en/2015/06/24/gary-german-aortic-valve-registry/" title="Read more" >...</a>

The aim of this study was to evaluate the safety and efficacy of the new device in patients with severe aortic stenosis at high surgical risk. We included 120 patients with a mean age of 84 years and the aortic valve area of 0.7 cm2. The device was successfully implanted in all patients with a<a href="https://solaci.org/en/2015/06/24/reprise-ii-lotus-valve-for-percutaneous-aortic-valve-replacement/" title="Read more" >...</a>